Industry-School Interface: Following Professional Education Model to Impart Pragmatic Business Edification

This intercourse aims to identify means by which the business education system can be aided to effectively meet the needs of the business-operating environment. Despite of the popularity of business and management education critics have been talking about business education to be less relevant to business needs. This study focuses on exploring the modes of exchange of knowledge between business schools and industry to facilitate practical learning. It mainly aims to get a holistic view of the extent to which an industry and school collaboration based system can ensure pragmatism in business education along with promises, issues and challenges such industry school interface can offer. The data collection for this hypothesized model will be collected from business executives, business school management and alumni. This intercourse will offer new insight into the business education system. The study results will be valuable towards bringing improvements to the existing business education system. Keywords: Business Education, Management, School - Industry Interface, Pragmatism, Industr

Systematic Literature Review of Social Entrepreneurship Phenomenon: Perspectives and Theoretical Lenses

Social entrepreneurship (SE) is an emerging subject in the field of entrepreneurship research since previous years. However, there has been a significant increase in social entrepreneurship research based on multifaceted literature reviews. Still, this field required more research to mature the concept of social entrepreneurship studies with different dimensions. The established SE literature shows a lack of studies classifying this phenomenon through the theoretical and practical lenses. The current study fills the gap by studying practical and theoretical perspectives of social entrepreneurship. This study used a systematic review spanning 2010 to 2020 to understand social entrepreneurship conceptual and theoretical perspectives. Based on the study findings, poverty reduction, economic growth, social innovation, job creation, and social entrepreneurship orientation is the cluster of social entrepreneurship. This study also describes few theories that explained the social entrepreneurship phenomenon, e.g. social capital theory, institutional theory, economic innovation theory, complex and ecosystem theory, holistic theory of individual decision making, and behavioural entrepreneurship theory in different perspectives; despite these theories, a multidimensional theoretical perspective needs to be discussed to explain social entrepreneurship comprehensively. Moreover, future directions are also suggested in this study to fill the potential in this field

A Systematic Review of Entrepreneurial Family: Perspectives and Theoretical

 The research on entrepreneurial family business is increasing from the last decades with different perspectives. The entrepreneurial family researches contributed different ways of conceptualizing the entrepreneurial family business based on highly complex literature reviews. Still, this field is emerging, and potential for further research to fill the gaps in different areas. The current research presented a systematic review based on the period of 2010 to 2020 for understanding family business content and theoretical perspective comprehensively. The study findings highlighted how entrepreneurial family business pursues through different conceptualization and theoretical perspectives. A plethora of study is found on family businesses worldwide based on organizational performance, business ownership, corporate governance, business succession and organizational culture. However, few studies corroborated theories to explain the entrepreneurial family business phenomenon. The theories discussed in this review are resource based view theory, agency theory, stewardship theory, multi and meso level theory and sociological theory for describing the entrepreneurial family business. Moreover, the future direction is also given in this study to fill the potential in this field

Detection of BCR-ABL kinase domain mutations in CD34+ cells from newly diagnosed chronic phase CML patients and their association with imatinib resistance

BCR-ABL kinase domain (KD) mutations, the most common cause of imatinib resistance, are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CP-CML) patients. Recent studies indicate pre-existing mutations (PEMs) can be detected in a higher percentage of CML patients using CD34+ stem/progenitor cells, and these mutations may correlate with imatinib resistance. We investigated KD mutations in CD34+ stem cells from 100 CP-CML patients by multiplex ASO-PCR and sequencing ASO-PCR products at the time of diagnosis. PEMs were detected in 32/100 patients and included F311L, M351T, and T315I. After a median follow-up of 30 months (range 8-48), all patients with PEMs exhibited imatinib resistance. Of 68 patients without PEMs, 24 developed imatinib resistance. Mutations were detected in 21 of these patients by ASO-PCR and KD sequencing. All 32 patients with PEMs had the same mutations. In imatinib-resistant patients without PEMs, we detected F311L, M351T, Y253F, and T315I mutations. All imatinib-resistant patients without T315I and Y253F mutations responded to imatinib dose escalation. In conclusion, BCR-ABL PEMs can be detected in a substantial number of CP-CML patients when investigated using CD34+ stem/progenitor cells. These mutations are associated with imatinib resistance, and mutation testing using CD34+ cells may facilitate improved, patient-tailored treatment

Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial

Background Post-partum haemorrhage is the leading cause of maternal death worldwide. Early administration of tranexamic acid reduces deaths due to bleeding in trauma patients. We aimed to assess the effects of early administration of tranexamic acid on death, hysterectomy, and other relevant outcomes in women with post-partum haemorrhage. Methods In this randomised, double-blind, placebo-controlled trial, we recruited women aged 16 years and older with a clinical diagnosis of post-partum haemorrhage after a vaginal birth or caesarean section from 193 hospitals in 21 countries. We randomly assigned women to receive either 1 g intravenous tranexamic acid or matching placebo in addition to usual care. If bleeding continued after 30 min, or stopped and restarted within 24 h of the first dose, a second dose of 1 g of tranexamic acid or placebo could be given. Patients were assigned by selection of a numbered treatment pack from a box containing eight numbered packs that were identical apart from the pack number. Participants, care givers, and those assessing outcomes were masked to allocation. We originally planned to enrol 15 000 women with a composite primary endpoint of death from all-causes or hysterectomy within 42 days of giving birth. However, during the trial it became apparent that the decision to conduct a hysterectomy was often made at the same time as randomisation. Although tranexamic acid could influence the risk of death in these cases, it could not affect the risk of hysterectomy. We therefore increased the sample size from 15 000 to 20 000 women in order to estimate the effect of tranexamic acid on the risk of death from post-partum haemorrhage. All analyses were done on an intention-to-treat basis. This trial is registered with ISRCTN76912190 (Dec 8, 2008); ClinicalTrials.gov, number NCT00872469; and PACTR201007000192283. Findings Between March, 2010, and April, 2016, 20 060 women were enrolled and randomly assigned to receive tranexamic acid (n=10 051) or placebo (n=10 009), of whom 10 036 and 9985, respectively, were included in the analysis. Death due to bleeding was significantly reduced in women given tranexamic acid (155 [1·5%] of 10 036 patients vs 191 [1·9%] of 9985 in the placebo group, risk ratio [RR] 0·81, 95% CI 0·65–1·00; p=0·045), especially in women given treatment within 3 h of giving birth (89 [1·2%] in the tranexamic acid group vs 127 [1·7%] in the placebo group, RR 0·69, 95% CI 0·52–0·91; p=0·008). All other causes of death did not differ significantly by group. Hysterectomy was not reduced with tranexamic acid (358 [3·6%] patients in the tranexamic acid group vs 351 [3·5%] in the placebo group, RR 1·02, 95% CI 0·88–1·07; p=0·84). The composite primary endpoint of death from all causes or hysterectomy was not reduced with tranexamic acid (534 [5·3%] deaths or hysterectomies in the tranexamic acid group vs 546 [5·5%] in the placebo group, RR 0·97, 95% CI 0·87-1·09; p=0·65). Adverse events (including thromboembolic events) did not differ significantly in the tranexamic acid versus placebo group. Interpretation Tranexamic acid reduces death due to bleeding in women with post-partum haemorrhage with no adverse effects. When used as a treatment for postpartum haemorrhage, tranexamic acid should be given as soon as possible after bleeding onset. Funding London School of Hygiene & Tropical Medicine, Pfizer, UK Department of Health, Wellcome Trust, and Bill & Melinda Gates Foundation

Unveiling femvertising: examining gratitude, consumers attitude towards femvertising and personality traits

AbstractThe raised awareness of women’s rights has resulted in their significant contribution to economic and societal advancement in the contemporary global paradigm. The promotion of female empowerment by various corporations has led to the emergence of femvertising as a significant trend in the media. The current research attempts to empirically examine the relationship between the message involvement of consumers and their attitude towards femvertising. The present study further investigates the potential mediating role of gratitude in the relationship between message involvement and attitude towards femvertising among consumers. Moreover, this study provides additional evidence supporting the notion that gratitude serves as a mediator in the association between feminist consciousness and attitude towards femvertising. In addition, the moderating influence of personality traits, specifically extraversion and agreeableness, on the indirect association between message involvement/feminist consciousness and attitude towards femvertising through the mediating mechanism of gratitude has been tested. The data collection process involved the utilization of a survey instrument, while the hypotheses were subjected to testing through the use of PROCESS macros for SPSS

Comparison of diagnostic accuracy of magnetic resonance spectroscopy with conventional magnetic resonance imaging for brain tumors and correlation with histopathology as gold standard

Background; Despite a large number of revolutionized advancements in Imaging technology clinicians are unable to get hundred percent accurate results. Multiple limitations have been observed in Imaging modalities. Multiple published trials are available online on the evaluations of these imaging modalities individually and in combinations to find out the level of accuracy of these technologies. Objective; This study was design to compare the diagnostic accuracy of MR Spectroscopy with MRI which is a conventional diagnostic tool for brain tumor diagnosis while keeping the Histopathology evaluation as Gold Standard. Methodology; The patients who fulfilled the inclusion criteria were included in study. All scans were carried out on GE 1.5 Tesla MR Scanner using head coil. Axial T1W, T2W, Fluid Attenuated Inversion Recovery (FLAIR), Sagittal T2W, Coronal Fluid Attenuation. Inversion Recovery (FLAIR) and T1W post- contrast Axial, Coronal and Sagittal images were acquired. MR spectroscopy was performed through single voxel technique. Final diagnosis was made on histopathology results. The reports of biopsy were co related with radiological diagnosis of MRI and MRS. Results; The study was conducted with 150 suspected cases. There were 85(56.7%) males and 65(43.3%) females. Histopathology 100(66.7%) cases were confirmed positive and 50(33.3%) negative.&nbsp

Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.

BACKGROUND: BCR-ABL kinase domain mutations are infrequently detected in newly diagnosed chronic-phase chronic myeloid leukemia (CML) patients. Recent studies indicate the presence of pre-existing BCR-ABL mutations in a higher percentage of CML patients when CD34+ stem/progenitor cells are investigated using sensitive techniques, and these mutations are associated with imatinib resistance and disease progression. However, such studies were limited to smaller number of patients. METHODS: We investigated BCR-ABL kinase domain mutations in CD34+ cells from 100 chronic-phase CML patients by multiplex allele-specific PCR and sequencing at diagnosis. Mutations were re-investigated upon manifestation of imatinib resistance using allele-specific PCR and direct sequencing of BCR-ABL kinase domain. RESULTS: Pre-existing BCR-ABL mutations were detected in 32/100 patients and included F311L, M351T, and T315I. After a median follow-up of 30 months (range 8-48), all patients with pre-existing BCR-ABL mutations exhibited imatinib resistance. Of the 68 patients without pre-existing BCR-ABL mutations, 24 developed imatinib resistance; allele-specific PCR and BCR-ABL kinase domain sequencing detected mutations in 22 of these patients. All 32 patients with pre-existing BCR-ABL mutations had the same mutations after manifestation of imatinib-resistance. In imatinib-resistant patients without pre-existing BCR-ABL mutations, we detected F311L, M351T, Y253F, and T315I mutations. All imatinib-resistant patients except T315I and Y253F mutations responded to imatinib dose escalation. CONCLUSION: Pre-existing BCR-ABL mutations can be detected in a substantial number of chronic-phase CML patients by sensitive allele-specific PCR technique using CD34+ cells. These mutations are associated with imatinib resistance if affecting drug binding directly or indirectly. After the recent approval of nilotinib, dasatinib, bosutinib and ponatinib for treatment of chronic myeloid leukemia along with imatinib, all of which vary in their effectiveness against mutated BCR-ABL forms, detection of pre-existing BCR-ABL mutations can help in selection of appropriate first-line drug therapy. Thus, mutation testing using CD34+ cells may facilitate improved, patient-tailored treatment

Sequences of ASO primers and corresponding annealing temperatures (bold nucleotides in the primers denote nucleotide changes corresponding to mutations).

*<p>Substitutions of amino acids; positions according to GenBank no. AAB60394for ABL type 1a.</p>**<p>Changes of nucleotide; positions according to GenBank no.M14752.</p>$<p>L (bp) = Primer length in base pairs.</p>#<p>A Tm =  Annealing temperature in degree Celsius.</p

Patients’ characteristics.

<p>Ph+<b> = </b>Philadelphia chromosome positive.</p><p>PEM = pre existing mutations.</p